Dr Walter joined Immatics Biotechnologies GmbH in 2005 where he became VP Immunology. For over 15 years he has been active in the field of cancer immunotherapy and a leader in human T-cell biology. In addition to supporting the development of the XPRESIDENT® technology platform, under his leadership, Immatics developed its powerful Immunomonitoring and T-cell receptor (TCR) discovery platforms to support the generation of safe and effective T-cell-based therapeutic modalities. In 2015, Dr Walter co-founded Immatics US, Inc. in Houston, Texas as a joint venture between Immatics and MD Anderson Cancer Center (MDACC) to develop next-generation adoptive cell therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas. As CSO, at Immatics US he leads a team that is responsible for Product Science, Process Development, Manufacturing, Quality Control and Program Management for Immatics’ cell therapy programs. Dr Walter is an inventor on numerous patents and patent applications and has co-authored more than 30 publications in prestigious peer-reviewed journals including Nature Medicine, Cell Reports, Brain and Blood. Dr Walter gained his PhD in Immunology from the University of Tuebingen, Germany.